Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACAM2000 Vaccination of Plasma Donors for VIGIV Production
NCT02443623Phase 4Completed
- Sponsor
- Emergent BioSolutions
- Start
- Sep 2015
- Primary completion
- Jul 2021
- Modality
- Prophylactic Vaccines, DNA Vaccines, Live Biotherapeutic Products
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of smallpox (vaccinia) vaccine, live in smallpox, sponsored by Emergent BioSolutions. Primary endpoints: Number of Vaccinated Participants With Adverse Events (AEs) Including Serious Adverse Events (SAEs) at Day 90, Number of Vaccinated Participants With Related Adverse Events at Day 90 and 1 more. Started Sep 2015; status: completed.
02
Drugs
smallpox (vaccinia) vaccine, live
03
Conditions
smallpox
Beyond the preview
Go deeper on NCT02443623.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02443623.